Pfizer enters the final stretch of May with short interest still rebuilding from its April lows, options traders remaining cautious, and a divided analyst community that nonetheless prices in meaningful recovery from a $25.66 close.
Short positioning has moved modestly higher since last week's note. SI % FF now reads 2.83%, up from 2.77% a week ago — a small increment, but it extends a trend that has carried shorts up roughly 18% over the past month. The May 8 peak of around 3.1% remains the high-water mark for the window; the subsequent pullback and partial re-build suggests short sellers are adding exposure incrementally rather than pressing aggressively. The lending market offers no squeeze catalyst: availability is extraordinarily loose at 4,527%, meaning there are more than 45 shares available to borrow for every one currently lent out. Cost to borrow is essentially flat at 0.47% annually — barely above the risk-free rate. The ORTEX short score has drifted to 36.3, marginally above the 35.8 reading from the previous note, and well within the moderate range it has occupied all month.
Options sentiment tells a similar, if slightly softened, story. The put/call ratio has eased fractionally to 0.92 from 0.93 last week, but remains above its 20-day average of 0.90. The z-score of 0.71 is notably lower than the 1.78 reading cited in the May 13 note — a meaningful relaxation. Investors are still running modestly above-average put exposure, but the urgency that characterised early-May positioning has faded. The 52-week PCR high of 1.05 remains a long way off.
The Street remains clustered around cautious neutrality, though with a few outliers that keep the debate alive. Most recent analyst moves have been target raises with ratings held flat: Morgan Stanley lifted to $28 (Equal-Weight), UBS to $27 (Neutral), and Citigroup to $27 (Neutral) — the pattern of incremental upgrades to targets without conviction on direction. The outlier is CICC, which initiated in mid-April with an Outperform and a $33 target, and Guggenheim, which holds a Buy with a $36 target — both well above the consensus mean of $29.19. On the other side, RBC's Underperform at $25 is now essentially at the current price. Bears point to gross-to-net adjustment headwinds on Vyndaqel and Ibrance; bulls counter with a $60 billion revenue base, strong international exposure and what the factor scores flag as an exceptional forward earnings recovery — the 12-month forward EPS year-on-year increase factor ranks in the 97th percentile, the strongest signal in the score set. The P/E has contracted 30 points over the past month to 8.8x, and price-to-book is 1.66x — neither stretched.
The institutional register is passive-heavy and stable. Vanguard and BlackRock together hold over 18% of shares, with both adding modestly in the most recent reported period. The more notable move comes from Fisher Asset Management, which added 53 million shares in Q1 2026 — a position build of that scale from an active manager warrants watching as subsequent filings arrive. Insider data is stale through early March, when a cluster of executive sales — including a $12.6 million disposal by CEO Albert Bourla on February 25 — registered at low significance scores, consistent with routine plan-based selling rather than a directional signal.
Among US-listed peers, BMY gained 3.3% on the week while AMRX fell 6.3%, illustrating the dispersion within pharma that has made sector calls difficult. PFE's flat-to-down week (-0.8%) places it in the middle of that range. The next confirmed earnings event is July 28 — at which point the gross-to-net adjustment debate the bears are focused on will either be validated or defused by actual Q2 numbers.
See the live data behind this article on ORTEX.
Open PFE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
